Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparative effectiveness of teriflunomide and dimethyl fumarate: A nationwide cohort study.
Buron MD, Chalmer TA, Sellebjerg F, Frederiksen J, Góra MK, Illes Z, Kant M, Mezei Z, Petersen T, Rasmussen PV, Roshanisefat H, Hassanpour-Kalam-Roudy H, Sejbæk T, Tsakiri A, Weglewski A, Sorensen PS, Magyari M. Buron MD, et al. Among authors: roshanisefat h. Neurology. 2019 Apr 16;92(16):e1811-e1820. doi: 10.1212/WNL.0000000000007314. Epub 2019 Mar 15. Neurology. 2019. PMID: 30877188 Free PMC article.
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.
Kapoor R, Ho PR, Campbell N, Chang I, Deykin A, Forrestal F, Lucas N, Yu B, Arnold DL, Freedman MS, Goldman MD, Hartung HP, Havrdová EK, Jeffery D, Miller A, Sellebjerg F, Cadavid D, Mikol D, Steiner D; ASCEND investigators. Kapoor R, et al. Lancet Neurol. 2018 May;17(5):405-415. doi: 10.1016/S1474-4422(18)30069-3. Epub 2018 Mar 12. Lancet Neurol. 2018. PMID: 29545067 Clinical Trial.
Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis Registry.
Papp V, Buron MD, Siersma V, Rasmussen PV, Illes Z, Kant M, Hilt C, Mezei Z, Roshanisefat H, Sejbæk T, Weglewski A, van Wingerden J, Geertsen SS, Bramow S, Sellebjerg F, Magyari M. Papp V, et al. Among authors: roshanisefat h. PLoS One. 2021 May 18;16(5):e0250820. doi: 10.1371/journal.pone.0250820. eCollection 2021. PLoS One. 2021. PMID: 34003862 Free PMC article.
Risk of hypertension in patients with multiple sclerosis treated with teriflunomide compared to dimethyl fumarate: A nationwide cohort study in Denmark.
Framke E, Sellebjerg F, Kant M, Stilund M, Jensen HB, Illes Z, Asgari N, Sejbaek T, Roug LC, Jensen MB, Schäfer J, Rasmussen PV, Christensen JR, Weglewski A, Prakash S, Magyari M; DMSG study group*. Framke E, et al. Mult Scler. 2024 Dec 4:13524585241299715. doi: 10.1177/13524585241299715. Online ahead of print. Mult Scler. 2024. PMID: 39632560
Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.
Confavreux C, O'Connor P, Comi G, Freedman MS, Miller AE, Olsson TP, Wolinsky JS, Bagulho T, Delhay JL, Dukovic D, Truffinet P, Kappos L; TOWER Trial Group. Confavreux C, et al. Lancet Neurol. 2014 Mar;13(3):247-56. doi: 10.1016/S1474-4422(13)70308-9. Epub 2014 Jan 23. Lancet Neurol. 2014. PMID: 24461574 Clinical Trial.
Appendicectomy and multiple sclerosis risk.
Roshanisefat H, Bahmanyar S, Hillert J, Olsson T, Montgomery SM. Roshanisefat H, et al. Eur J Neurol. 2011 Apr;18(4):667-9. doi: 10.1111/j.1468-1331.2010.03147.x. Eur J Neurol. 2011. PMID: 20629715
15 results